[{"id":"4826d46f-f39c-4ef9-9e0b-32005bc2ffb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05865002","created_at":"2024-02-01T04:20:40.302Z","updated_at":"2024-07-02T16:35:21.468Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)","source_id_and_acronym":"NCT05865002","lead_sponsor":"Aurigene Discovery Technologies Limited","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AUR-107"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-01-31"},{"id":"f3fa543f-eaf5-4acd-a3d9-1a89668bc625","acronym":"","url":"https://clinicaltrials.gov/study/NCT03568656","created_at":"2021-01-18T17:33:48.014Z","updated_at":"2024-07-02T16:35:22.821Z","phase":"Phase 1/2","brief_title":"Study to Evaluate CCS1477 in Advanced Tumours","source_id_and_acronym":"NCT03568656","lead_sponsor":"CellCentric Ltd.","biomarkers":" MYC • AR • ARID1A • CREBBP","pipe":" | ","alterations":" ARID1A mutation • CREBBP mutation • EP300 mutation","tags":["MYC • AR • ARID1A • CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • CREBBP mutation • EP300 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Tecentriq (atezolizumab) • Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • inobrodib (CCS1477)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 07/23/2018","start_date":" 07/23/2018","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-01-19"}]